您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > PTC-209 hydrobromide
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PTC-209 hydrobromide
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PTC-209 hydrobromide图片
CAS NO:1217022-63-3
包装与价格:
包装价格(元)
100mg电议
250mg电议
500mg电议

产品介绍
PTC-209 hydrobromide 是一种特定的BMI-1抑制剂,在 HEK293T 细胞系中的IC50为 0.5 μM。PTC-209 hydrobromide 不可逆转地损害结直肠癌起始细胞 (CICs)。PTC-209 hydrobromide 显示有效的抗骨髓瘤活性并损害肿瘤微环境。
生物活性

PTC-209 hydrobromide is a specificBMI-1inhibitor with anIC50of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs). PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment[1][2].

IC50& Target

IC50: 0.5 μM (BMI-1, in HT1080 tumor cells)[1]

体外研究
(In Vitro)

PTC-209 (0.01-10 μM; 24-72 hours) induces a concentration- and time-dependent decrease in the cellular viability of all cell lines tested[2].
PTC-209 (1-2.5 μM) inhibits STAT3 phosphorylation in A549 lung cancer cells and MDA-MB-231 breast cancer cells[2].

Cell Viability Assay[2]

Cell Line:Lung (LNM35, A549 cells), breast (MDA-MB-231 and T47D cells), and colon (HT-29, HCT-116, and HCT8/S11 cells)
Concentration:0.01-10 μM
Incubation Time:24, 48, and 72 hour
Result:Induced a concentration- and time-dependent decrease in the cellular viability of all cell lines tested.
体内研究
(In Vivo)

PTC-209 (60 mg/kg body weight; subcutaneously; once a day for 11 days) significantly reduces tumor volume[2].

Animal Model:Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor)[1]
Dosage:60 mg/kg body weight
Administration:Subcutaneously; once a day for 11 days
Result:Significantly reduced tumor volume.
分子量

576.10

Formula

C17H14Br3N5OS

CAS 号

1217022-63-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.